【摘要】：目的:探討自體外周血造血干細(xì)胞移植(autologous peripheral blood stem cell transplantation,APBSCT)治療惡性淋巴瘤的療效。方法:回顧性分析2005至2015年于我院血液科接受APBSCT治療的99例惡性淋巴瘤患者的臨床資料。結(jié)果:(1)99例患者中,男性68例,女性31例,中位發(fā)病年齡44(16~69)歲。其中,非霍奇金淋巴瘤(non-Hodgkin’s lymphoma,NHL)88例(BNHL 60例,T-NHL 28例),霍奇金淋巴瘤11例;國(guó)際預(yù)后指數(shù)(international prognostic index,IPI)評(píng)分≤2和IPI評(píng)分2分別為78例和21例;移植前處于完全緩解(complete remission,CR)狀態(tài)的患者65例;臨床分期Ⅲ~Ⅳ期者84例;移植前化療中,31例B-NHL應(yīng)用利妥昔單抗聯(lián)合化療,29例未使用。(2)全部患者動(dòng)員后均采集到足夠的造血干細(xì)胞,其中2例未獲得全面造血重建,后因膿毒血癥死亡,其余患者均造血重建成功。全組中位隨訪時(shí)間25(0~109)個(gè)月,3年總生存(overall survival,OS)率和無(wú)進(jìn)展生存(progression-free survival,PFS)率分別為74.70%和61.60%。移植前達(dá)CR狀態(tài)患者的3年OS率和PFS率分別為86.20%和76.90%;未達(dá)CR狀態(tài)的3年OS率和PFS率分別為52.90%和32.40%;兩組相比OS率和PFS率差異均有統(tǒng)計(jì)學(xué)意義(P=0.000,P=0.000)。移植前IPI評(píng)分處于低中危組(IPI≤2)患者的3年P(guān)FS率為69.20%,中高危組(IPI2)3年P(guān)FS率為33.30%,2組間PFS率差異有統(tǒng)計(jì)學(xué)意義(P=0.000)。B-NHL患者的3年P(guān)FS率與T-NHL相比差異有統(tǒng)計(jì)學(xué)意義(3年P(guān)FS率70.00%vs.42.90%,P=0.019)。B-NHL中應(yīng)用1~2療程利妥昔單抗聯(lián)合化療組、3~4療程組與未使用組相比OS率和PFS率差異均無(wú)統(tǒng)計(jì)學(xué)意義(P=0.152,P=0.368)。結(jié)論:APBSCT是治療惡性淋巴瘤安全、有效的方法;移植前未達(dá)CR狀態(tài)、移植前IPI評(píng)分2以及T-NHL為影響惡性淋巴瘤的預(yù)后不良因素。
[Abstract]:Objective: to evaluate the efficacy of autologous peripheral blood stem cell transplantation (autologous peripheral blood stem cell transplantation,APBSCT) in the treatment of malignant lymphoma. Methods: the clinical data of 99 cases of malignant lymphoma treated with APBSCT from 2005 to 2015 were analyzed retrospectively. Results: (1) among 99 patients, 68 were male and 31 were female. The median age of onset was 44 (1669) years. There were 88 cases of non-Hodgkin 's lymphoma (BNHL 60 cases, T-NHL 28 cases), 11 cases of Hodgkin's lymphoma, 78 cases of international prognostic index (international prognostic index,IPI) score 鈮，

本文編號(hào)：2293158